ArticleIranian journal of pathology2026
Immunohistochemical Expression of HLA Classes I and II in Neonatal Cholestatic Liver Disease.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Neonatal cholestasis (NC) is a significant clinical condition involving hepatobiliary dysfunction, often accompanied by immunological alterations regardless of etiology. Human leukocyte antigens (HLA) molecules, particularly classes I and II, play roles in autoimmune liver diseases. Previous studies showed inconsistent results regarding their expression in hepatocytes and cholangiocytes under normal and pathological conditions. This study aimed to evaluate immunohistochemical expression of HLA I and II in NC. Methods: A retrospective analysis included 45 pediatric NC cases: 27 with biliary atresia (BA), 13 with progressive familial intrahepatic cholestasis (PFIC), and 5 with idiopathic neonatal hepatitis (INH). Twenty normal liver samples from adult transplant donors served as controls. Immunohistochemistry was used to evaluate HLA I and II expression in hepatocytes and cholangiocytes. Results: Control livers lacked detectable HLA I and II expression. In NC cases, HLA I was expressed in hepatocytes (84.4%) and all cholangiocytes, while HLA II was expressed in both cell types across all cases. BA cases showed significantly higher cholangiocyte expression of HLA I (p = 0.001) and II (p < 0.001) compared to PFIC and INH. HLA I expression was linked to cholangiocyte proliferation (p = 0.005) and inversely with lobular inflammation (p = 0.027). Strong HLA II expression in hepatocytes correlated with severe portal inflammation (p = 0.048), while in cholangiocytes, to proliferation, neutrophilic cholangitis (p = 0.05), and mild lobular inflammation (p = 0.043). Conclusion: HLA I and II are upregulated in NC, especially in BA, which correlates with disease severity, suggesting a role in pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.